Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Am J Hematol. 2023 Apr 6;98(6):932–939. doi: 10.1002/ajh.26924

Table 1.

Baseline Characteristics

All Patients
(n = 42)
IV Administration
(n = 28)
SC Administration
(n = 14)
P-value
Female Sex, n (%) 24 (57) 15 (54) 9 (64) 0.51
Age (y), median (IQR) 32.5 (22.3, 62.3) 29.5 (22.0, 60.0) 37.5 (23.8, 64.8) 0.85
Disease severity, n (%)
SAA 38 (90) 25 (89) 13 (93) 1.0
VSAA 4 (10) 3 (11) 1 (7)
Number of Prior Immunosuppressive Treatments, n (%)
One 31 (74) 23 (82) 8 (57) 0.75
Two 9 (21) 6 (21) 3 (21)
Three 1 (2) 1 (4) 0
Four 0 0 0
Five 1 (2) 0 1 (7)
Laboratory Values, median (IQR)
Hemoglobin (g/dL) 8.8 (8.4, 9.2) 8.8 (8.4, 9.2) 8.8 (7.7, 9.2) 0.93
Platelets (x109/L) 28.0 (17.3, 43.0) 31.5 (19.5, 42.3) 23.0 (10.8, 44.5) 0.45
Absolute Neutrophil Count (x109/L) 0.8 (0.4, 1.3) 0.7 (0.4, 1.2) 0.8 (0.4, 1.5) 0.62
Absolute Lymphocyte Count (x109/L) 0.2 (0.1, 0.4) 0.2 (0.1, 0.5) 0.3 (0.1, 0.4) 1
Absolute Reticulocyte Count (x109/L) 29.9 (14.0, 46.8) 30.6 (15.9, 43.7) 21.8 (12.0, 46.8) 0.87
PNH Clone, n (%) 19 (45) 10 (36) 9 (64) 0.18

Abbreviations: IQR = interquartile range; IV = intravenous; PNH = paroxysmal nocturnal hemoglobinuria; SAA = severe aplastic anemia; SC = subcutaneous; VSAA = very severe aplastic anemia